Erratum to: Targeting CGRP: A New Era for Migraine Treatment

Stephanie Wrobel Goldberg¹ · Stephen David Silberstein¹

Published online: 11 April 2016
© Springer International Publishing Switzerland 2016

Erratum to: CNS Drugs (2015) 29:443–452 DOI 10.1007/s40263-015-0253-z

Errors have subsequently been identified in the original publication, and the following corrections should be noted:

Page 447, column 1, paragraph 4, lines 6–13: The following two sentences, which previously read:

Four fully humanized mAbs are in different stages of phase I and II clinical trial investigation for the treatment of migraine. Three are targeting the CGRP ligand: LY2951742 (developed by Eli Lilly and Co.); ALD-403 (developed by Alder Biopharmaceuticals); and TEV-48125

(LBR-101) (developed by Teva Pharmaceuticals); and one against its receptor, AMG 334 (in development by Amgen).

Should read:

Four mAbs are in different stages of phase I and II clinical trial investigation for the treatment of migraine. Three fully humanised mAbs target the CGRP ligand: LY2951742 (developed by Eli Lilly and Co.); ALD-403 (developed by Alder Biopharmaceuticals); and TEV-48125 (LBR-101) (developed by Teva Pharmaceuticals); and one fully human mAb targets the CGRP receptor, AMG 334 (in development by Amgen).

The online version of the original article can be found under doi:[10.1007/s40263-015-0253-z](https://doi.org/10.1007/s40263-015-0253-z).

✉ Stephanie Wrobel Goldberg
stephwg@gmail.com

Stephen David Silberstein
stephen.silberstein@jefferson.edu

¹ Department of Neurology, Jefferson Headache Center, Thomas Jefferson University, 900 Walnut Street, Suite 200, Philadelphia, PA 19107, USA